HER2 status and disparities in luminal breast cancers

National Comprehensive Care Network guidelines for adjuvant treatment of invasive breast cancer are based on HER2 and hormone receptor (HR) status, where HR+ disease encompasses all estrogen receptor (ER)+ and/or progesterone receptor (PR)+ tumors. We sought to explore clinical and demographic diffe...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Med
Main Authors: Holowatyj, Andreana N., Ruterbusch, Julie J., Ratnam, Manohar, Gorski, David H., Cote, Michele L.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2016
Subjects:
Cancer Prevention
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4893351/
https://ncbi.nlm.nih.gov/pubmed/27250116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.757
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items